ZAP Surgical Systems, a US-based medical technology company developing non-invasive robotic brain surgery systems, has secured $36 million in financing led by Catalio Capital Management, with continued investment from Baheal, its strategic partner in China.
The funding will support international expansion of the company’s ZAP-X Gyroscopic Radiosurgery platform across academic medical centers, community hospitals, and physician-led practices. ZAP also plans to increase manufacturing capacity to support its growing international operations.
Founded in 2014 by Dr. John R. Adler, who serves as CEO, ZAP Surgical Systems is headquartered in San Carlos, California. The company develops robotic radiosurgery technology for treating brain tumors and other neurological conditions without surgical incisions.
Its ZAP-X platform uses gyroscopic motion and a linear accelerator to deliver targeted radiation. The system incorporates shielding technology designed to reduce the need for conventional radiation treatment vaults and operates without radioactive cobalt sources.
ZAP recently shipped its 50th ZAP-X system and reported that nearly 10,000 patients have received treatment using its technology worldwide.
Beyond established neuro-oncology applications, the company is researching radiomodulation, an investigational approach using precisely targeted, low-dose radiation to influence neural activity. ZAP has reported preliminary findings from a first-in-human pilot study involving treatment-resistant depression and is planning broader clinical trials exploring depression and addiction. These applications remain investigational.
The latest financing follows a $78 million Series E round announced in November 2024, led by Qingdao Baheal Medical. That investment supported the manufacturing, commercialization, and distribution of the ZAP-X platform.
